Form 4 for ENTA ENANTA PHARMACEUTICALS INC
Accepted 2022-01-18 00:00:00 ET · period of report 2022-01-15 · accession 0001062993-22-001104 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-01-18 | 2022-01-15 | ENTA | Luly Jay R. | Pres, CEO, Dir | M - OptEx | $11.77 | +10.1K | 710.8K | +1% | +$118.4K |
| D | 2022-01-18 | 2022-01-15 | ENTA | Luly Jay R. | Pres, CEO, Dir | M - OptEx | $0.00 | -10.1K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-15 | M | A | 10,063 | $11.77 | 710,791 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2022-01-15 | M | D | 10,063 | $0.00 | 0 | D | $11.77 · — to 2022-06-20 | 10,063 Common Stock | (F1) 100% of the shares subject to the option are fully vested and exercisable. |